biostudies-literatureUnknown192(1)Rodriguez-Pinilla SMTakedaTakeda Pharmaceutical CompanyWe investigated the clinicopathological features and prognostic factors of patients with peripheral T-cell lymphoma (PTCL) in 13 sites across Spain. Relevant clinical antecedents, CD30 expression and staining pattern, prognostic indices using the International Prognostic Index and the Intergruppo Italiano Linfomi system, treatments, and clinical outcomes were examined. A sizeable proportion of 175 patients had a history of immune-related disorders (autoimmune 16%, viral infections 17%, chemo/radiotherapy-treated carcinomas 19%). The median progression-free survival (PFS) and overall survival (OS) were 7·9 and 15·8 months, respectively. Prognostic indices influenced PFS and OS, with a higher number of adverse factors resulting in shorter survival (P < 0·001). Complete response (CR) to treatBritish journal of haematology82-99https://www.ebi.ac.uk/biostudies/studies/S-EPMC7818499biostudies-literatureClinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study.PMC7818499Rodriguez GCarpio CSanchez JAliste CCaballero DBorrero JJGomez Codina JMayordomo-Aranda EGrande MLopez Jimenez JCliment FBlanco Munez OJGonzalez AJNavarro BPiris MACordoba RPerez Seoane CRodriguez-Pinilla SMBendana AMartinez Pozo AMontoto CGonzalez Farre BGonzalez de Villambrosia SDomingo-Domenech EBellas CGarcia-Cosio MCastellvi JRuiz-Zorrilla AfalseClinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study.We investigated the clinicopathological features and prognostic factors of patients with peripheral T-cell lymphoma (PTCL) in 13 sites across Spain. Relevant clinical antecedents, CD30 expression and staining pattern, prognostic indices using the International Prognostic Index and the Intergruppo Italiano Linfomi system, treatments, and clinical outcomes were examined. A sizeable proportion of 175 patients had a history of immune-related disorders (autoimmune 16%, viral infections 17%, chemo/radiotherapy-treated carcinomas 19%). The median progression-free survival (PFS) and overall survival (OS) were 7·9 and 15·8 months, respectively. Prognostic indices influenced PFS and OS, with a higher number of adverse factors resulting in shorter survival (P < 0·001). Complete response (CR) to treat2021-01-01T00:00:00Z2021 Jan2025-04-26T06:29:30.966Z2021-02-21T02:31:07ZS-EPMC78184993242684710.1111/bjh.16741